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Abstract
S-nitrosoglutathione (GSNO) is a nitric oxide (NO) donor, which exerts antioxidant, anti-
inflammatory, and microbicidal actions. Intragingival application of GSNO was already
shown to decrease alveolar bone loss, inflammation and oxidative stress in an experimental
periodontal disease (EPD) model. In the present study, we evaluated the potential thera-
peutic effect of topical applications of hydroxypropylmethylcellulose (HPMC)/GSNO solu-
tions on EPD in Wistar rats. EPD was induced by placing a sterilized nylon (3.0) thread
ligature around the cervix of the second left upper molar of the animals, which received topi-
cal applications of a HPMC solutions containing GSNO 2 or 10 mM or vehicle (HPMC solu-
tion), 1 h prior to the placement of the ligature and then twice daily until sacrifice on day 11.
Treatment with HPMC/GSNO 10 mM solution significantly reduced alveolar bone loss, oxi-
dative stress and TNF-α e IL-1β levels in the surrounding gingival tissue, and led to a
decreased transcription of RANK and TNF-α genes and elevated bone alkaline phospha-
tase, compared to the HPMC group. In conclusion, topical application of HPMC/GSNO solu-
tion is a potential treatment to reduce inflammation and bone loss in periodontal disease.
Introduction
Periodontal diseases, including gingivitis, are highly prevalent [1] and characterized by the
inflammation of the periodontal connective tissue with influx of inflammatory cells, especially
polymorphonuclear leukocytes, monocytes and macrophages from the peripheral blood into
the periodontal connective tissue. While gingivitis does not affect the underlying supporting
structures of the teeth, periodontitis results in loss of connective tissue and bone support [2,3]
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and can progress to bone destruction, tooth mobility and finally, tooth loss. In turn, the bacte-
rial pathogens in the dental plaque stimulate host cells to release various pro-inflammatory
cytokines such as IL-1 and TNF-α, which attract polymorphonucleocytes (PMNs) to the site of
infection. In addition, the activation of neutrophils by periodontopathogenic microorganisms
with the consequent production of reactive oxygen species (ROS) may induce periodontal tis-
sue breakdown [4].
Endogenously produced nitric oxide (NO) is a mediator of several physiological and patho-
physiological processes whose actions include the inactivation of ROS and the blocking of radi-
cal propagation reactions [5,6]. It has also been demonstrated that NO has a variety of effects on
bone, suppressing osteoclast bone resorption and promoting the growth of osteoblasts [7–13].
It has been demonstrated that intragingival administration of S-nitrosoglutathione (GSNO),
an endogenously found NO carrier and donor decreases bone resorption in vivo in a animal
model of periodontitis [14], similarly to what has been shown in vitro with L-arginine supple-
mentation [15]. GSNO has already displayed microbicidal actions [16–18] as well as wound
healing action [19] in several other studies. These results encouraged us to investigate the
potential beneficial actions that could be obtained from the topical application of GSNO for
treating periodontitis, avoiding thus an invasive approach. For this purpose, we incorporated
GSNO in hydroxypropylmethylcellulose (HPMC) solution. HPMC is widely used as a hydro-
philic pharmaceutical vehicle for drug delivery systems and due to its mucoadhesive property,
comprises an adequate matrix for the topical NO delivery from GSNO in the oral cavity.
Materials and Methods
Reagents and drugs
Hydroxypropylmethylcellulose (HPMC; Mn 90000), glutathione (GSH), sodium nitrite
(NaNO2), phosphate-buffered saline (PBS) pH 7.4, acetone and hydrochloric acid (HCl) were
purchased from Sigma-Aldrich (St. Louis, MO, USA). All reagents were analytical grade and
used as received. All experiments were performed using deionized water from a Millipore
Milli-Q gradient filtration system (Billerica, MA, USA).
S-nitrosoglutathione synthesis
S-nitrosoglutathione (GSNO) was synthesized by reacting GSH with NaNO2 in equimolar
amounts in acidic solution (HCl, pH 2.0) as described elsewhere [19]. Solid, dry GSNO was
stored protected from light at -20°C for further use.
Preparation of HPMC/GSNO solutions
To incorporate GSNO in the HPMC solutions at final concentrations of 2.0 mM (HPMC/
GSNO 2.0 mM) and 10 mM (HPMC/GSNO 10 mM), appropriate amounts of solid GSNO
were weighted and transferred initially to PBS solution in falcon tubes. After complete GSNO
dissolution under stirring, appropriate volumes of the GSNO solutions were transferred to
other falcon tubes containing solid HPMC in amounts calculated to obtain a final HPMC con-
centration of 1.25 wt% in all cases. The tubes were stirred for 5 min in a vortex and transferred
to a refrigerator at 8°C, where they stayed for 2 h to assure complete dissolution of the HPMC
in the GSNO solutions. The GSNO solutions and HPMC/GSNO solutions were protected from
room light with aluminum foil during all the procedures in order to avoid GSNO photodecom-
position. The prepared formulations were used immediately in the topical applications and
stored back in the refrigerator after use. The formulations were discarded after 3 days of
storage.
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Animals
Male Wistar rats from the Federal University of Ceará, weighting 200 to 250 g were housed in
temperature-controlled rooms under 12 hour light-dark cycles and received water and food ad
libitum. Surgical procedures and animal treatments were conducted in accordance with the
guidelines of the Animal Research Ethics Committee (Comissão de Ética em Pesquisa Animal—
CEPA/DFF/FAMED/UFC—Permit number: 10/2013), of the Federal University of Ceará, Bra-
zil, who approved all the procedures involving the animals. All efforts were made to minimize
suffering.
Experimental Periodontal Disease Protocol
Experimental Periodontal Disease (EPD) was induced as previously described [20–21].Briefly,
the animals were anesthetized with ketamine (90 mg/kg intraperitoneally) and xylazine (10
mg/kg intraperitoneally) and a sterilized nylon (0.3) thread ligature was placed around the cer-
vix of the second left maxillary molar. The ligature was then knotted on the vestibular side of
the tooth, so it remained subgingival on the palatal side and supragingival on the buccal side.
The animals were euthanized with an overdose of ketamine and xylazine (300/30mg/kg; i.p.)
on day 11th.
Topical application of HPMC/GSNO solutions
The animals were divided into groups of 6 animals each and received topical applications of
HPMC/GSNO 2.0 mM or HPMC/GSNO 10.0 mM. The solutions were applied using small cot-
ton swabs with a gentle massage to both palatal and vestibular sides of the left maxillary molars
gingiva, starting 1 hour before the placement of the ligature and twice daily until euthanasia on
the 11th day. Control groups consisted of animals subjected to the surgical procedure that
received only the vehicle (HPMC) and a group of animals not subjected to experimental peri-
odontitis (normal).
Alveolar Bone Loss
The animals were euthanized 11 days after the placement of the ligature and the maxillae were
excided and fixed in 10% buffer formalin. After 24 hour, the left maxillae were defleshed and
stained with methylene blue (1%) to differentiate bone from teeth, fixed in a piece of wax and
photographed. The digital images were subjected to alveolar bone loss analysis using the Image
J software, as described previously [22]. In this procedure, the area (mm2) corresponding to the
exposed roots of the molars (no bone covering them at all) was calculated and subtracted from
the corresponding area (mm2) of the normal group. All acquired images were compared to a
well-known area (1.0 x 1.0 mm2).
Histopathological Analysis
For the histopathological analysis, the maxillae were excised, fixed in 10% neutral-buffered for-
malin and demineralized in EDTA. The specimens were then dehydrated, embedded in paraffin,
and sectioned along the molars in a mesiodistal plane for hematoxylin and eosin staining. Three
sections of 4 μm each, corresponding to the area between the first and second molars were eval-
uated under light microscopy using a 0 to 3 score grade [21,23], as following: 0- absence or dis-
crete cellular infiltration (inflammatory cell infiltration is space and restricted to the region of
the marginal gingival) and preserved alveolar process and cementum; 1- moderate cellular infil-
tration (inflammatory cellular infiltration present all over the insert gingival), some but discrete
alveolar process resorption and intact cementum; 2- Accentuated cellular infiltration
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(inflammatory cellular infiltration present in gingival and periodontal ligament), moderate deg-
radation of the alveolar process and partial destruction of cementum; 3- Accentuated cellular
infiltrate, complete resorption of the alveolar process and severe destruction of cementum.
Plasma Bone Alkaline Phosphatase (BALP)
Blood samples were collected from retro-orbital plexus, under anesthesia with a mixture of
ketamine and xylazine (90/10 mg/kg; i.p.), before ligature (on day 0) and immediately before
the euthanasia on the 11th day in order to obtain plasma concentration of alkaline phosphatase
using the thermo-activation method, as previously described [24]. The samples were heated up
to 56°C for 10 minutes. Serum levels of BALP (a thermosensitive isoform of the total alkaline
phosphatase, TALP), were calculated by subtracting the concentration of the heated alkaline
phosphatase in serum from the concentration of TALP in serum. The analysis was performed
according to the manufacturer’s instructions (Labest1, Lagoa Santa, MG, Brazil). The results
were expressed as Bone Alkaline Phosphatase variation on day 11 (U/L) compared to the values
obtained before the EPD induction, on day 0.
Malonaldehyde and Reduced Glutathione (GSH) Gingival Levels
To evaluate the effect of HPMC/GSNO solutions on the oxidative stress, reduced glutathione
(GSH), an antioxidant and malonaldehyde, a marker for oxidative stress, were measured in the
gingival tissue collected on day 11. Lipid peroxidation was measured as malonaldehyde (MDA)
production through the thiobarbituric acid reaction [25] in the gingival tissue of rats. Briefly,
250 μl of 10% homogenate of gingival tissue were mixed with 1.5 ml of 1% H3PO4 and 0.5 ml
of 0.6% thiobarbituric acid aqueous solution and the mixture was stirred and heated in boiling
water for 45 minutes. After cooling, 2 ml of n-butanol were added and the mixture was homog-
enized. The butanol layer was separated, and the difference between the optical densities at 535
and 520 nm was used for calculating the MDA concentrations, which were expressed as nano-
mol of MDA per gram of gingival tissue.
To evaluate the reduced glutathione (GSH) levels, the gingivae were first homogenized
(400 μl of a 10 wt% tissue solution prepared in 0.02 M EDTA). After that, 320 μl of distilled
water and 80 μL of 50% trichloroacetic acid (TCA) were added, followed by centrifugation at
3000 rpm for 15 min at 4°C. The supernatant was collected (400 mL) and added to 800 μL of
0.4 M Tris buffer at pH 8.9 and 20 μL of 0.01 M DTNB. The absorbance of each sample was
measured at 412 nm, and the results were described as μg of GSH per milligram of tissue.
Nitrite/nitrate (NOx) Gingival Levels
On day 11 after EPD induction, the gingivae surrounding the upper left molars were removed
for nitrite/nitrate (NOX) quantification using the Griess method [26]. Firstly, nitrate was
reduced to nitrite by incubation with nitrate reductase and nicotinamide adenine dinucleotide.
Then, the Griess reagent (1% sulfanilamide and 0.1% naphthyl ethylenediamine dihydrochlor-
ide in 5% phosphoric acid) was added, and the total concentration of nitrite was evaluated
through its absorbance at 540 nm, assigned to the Griess reaction adduct. A calibration curve
was obtained by incubating sodium nitrite (10 to 200 μM) with the Griess reagent. Nitrate/
nitrite levels were expressed as micromole per milligram of gingival tissue.
Quantification of Cytokines Gingival Levels
The gingivae surrounding the upper left molars were removed on the 11th day for and Tumor
Necrosis Factor Alpha and Interleukin-1β (TNF-α and IL-β; DuoSet Elisa Development kit,
Topical S-Nitrosoglutathione Prevents Alveolar Bone Resorption
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R&D Systems, Minneapolis, MN, USA) measurements. The quantification of the cytokines con-
tained in the samples was performed using an enzyme-linked immunosorbent assay (ELISA), as
previously described [27,28]. TNF-α and IL-β levels in the gingival tissue were determined using
respective standard curves. The results are expressed as pg/ml of TNF-α or IL-β.
Immunohistochemical staining for inducible nitric oxide synthase (iNOS),
receptor activator of the nuclear factor kappa-B (RANK) and Tartrate-
resistant acid phosphatase (TRAP) and nitrotyrosine
After the animals were sacrificed on the 11th day, the maxillae were excised, fixed in 10% neu-
tral-buffered formalin and demineralized in 10% EDTA. The immunohistochemical for iNOS,
RANK and TRAP were performed using the avidin–biotin–peroxidase method [27,28] in for-
malin-fixed, paraffin-embedded tissue sections (4 μm thick) and mounted on poly-L-lysine-
coated microscope slides. The sections were deparaffinized and rehydrated through xylene and
graded alcohols. After antigen retrieval, endogenous peroxidase was blocked (30 minutes) with
3% (v/v) hydrogen peroxide and washed in phosphate-buffered saline (PBS). Sections were
incubated overnight (4°C) with primary polyclonal rabbit anti-iNOS antibody (1:200), primary
polyclonal rabbit anti-RANK (1:200) and primary polyclonal rabbit anti-TRAP (1:200) or pri-
mary mouse monoclonal anti-nitrotyrosine (1:200). All the antibodies were diluted in PBS plus
bovine serum albumin (BSA). The slides were then incubated with biotinylated goat anti-rabbit
diluted 1:200 in PBS–BSA. After washing, the slides were incubated with avidin–biotin–horse-
radish peroxidase conjugate for 30 min, according to the protocol of the manufacturer. iNOS,
RANK and TRAP and nitrotyrosine were visualized with the chromogen 3,3 diaminobenzidine
(DAB), after 2 minutes of incubation. Negative control sections were processed simultaneously
as described above but with the first antibody being replaced by 5% PBS–BSA. Slides were
counterstained with hematoxylin, dehydrated in a graded alcohol series, cleared in xylene, and
coverslipped. The quantitative estimation of DAB products from immunostaining was deter-
mined from digital images of at least ten different areas of each section (from four specimens
per group), on 400x magnification, using Photoshop software. The immunostaining was calcu-
lated dividing the DAB positive staining (immunostaining positive pixels) by the number of
pixels per image, as previously described [29].
Quantitative PCR analysis of TNF-α, RANK and RANKL/OPGmRNA
levels
Expression of mRNA for TNF-α, RANK, RANK-L and OPG was determined by quantitative
real-time polymerase chain reaction (qPCR). RNA was extracted from gingival tissue using the
AurumTM Total RNA Fatty and Fibrous Tissue Kit (Bio-Rad, CA, USA) following the manufac-
turer’s instructions. The quality of the RNA was analyzed by 260/280 ratio, and quantified by
UV absorption using NanoDrop (Thermo scientific, Wilmington, DE, USA). One microgram
of total RNA from the intestinal samples in a final volume of 20 μl were reverse-transcribed
into cDNA in the C1000 Touch™ Termal Cycler system with the iScript™ cDNA synthesis kit
from Bio-Rad. Real-time quantitative PCR analysis of the mRNA was performed in an CFX96
Touch™ real-time PCR detection system instrument from Bio-Rad using the iQTM SYBR1
Green Supermix (Bio-Rad, CA, USA) as indicated by the manufacturer. qPCR was performed
for 35 cycles under the following conditions: denaturation 95°C, 30 s; annealing 60°C, 30 s;
extension, 25°C, 50 s. All samples were run in duplicate, and the relative mRNA expression
level was determined after normalizing all values to those of GAPDH. All samples were evalu-
ated for the dissociation characteristics of the double-stranded DNA during heating (melting
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curve analysis). The relative gene expression was determined using the 2-ΔΔCt method [30] with
GAPDH as the housekeeping gene. The primer pairs used in this study are shown in Table 1.
Statistical Analysis
Data are presented as means ± standard error (SEM) or as medians when appropriate. Univari-
ate Analysis of Variance followed by Bonferroni test was used to compare means and Kruskal–
Wallis and Dunn tests were used to compare medians. P< 0.05 was considered significant. All
analyses were performed using GraphPad Prism 6 software, San Diego, CA, USA.
Results
Alveolar Bone Loss
Local administration of HPMC/GSNO 10 mM solution 1 hour before the placement of the liga-
ture and twice daily for 11 days resulted in a significant inhibition of alveolar bone loss (Figs 1
and 2E), compared to the hemimaxillae of animal groups that received the vehicle only
(HPMC; Figs 1 and 2C). No significant bone loss was observed in the normal groups (Figs 1
and 2A).
Table 1. Description of biomarkers, gene, primer sequences and NCBI accession numbers.
Biomarkers Gene Primer sequence (5’-3’) NCBI
Proinflammatory cytokines TNF-α S-GACCCTCACACTCAGATCATCTTCT A-TGCTACGACGTGGGCTACG NM-012675
Bone markers RANK S-AGGGAAAACGCTGACAGCTAA A- CCAACACAATGGTCCCCTGA NM_001271235
RANK-L S-GCCAACCGAGACTACGGCAA A-GAACATGAAGCGGGAGGCG NM_057149
OPG S-CCTAGAGAGAAATGTCGTAGGATT A-CATTCCACACTGGAAACCTGA NM_012870
Reference gene GAPDH S-TGATTCTACCCACGGAAGTT A-TGATGGGTTTCCCATTGATGA NM_017008
doi:10.1371/journal.pone.0153716.t001
Fig 1. Effect of topical application of HPMC/GSNO solutions on alveolar bone loss in experimental
periodontitis. Data represent the mean ± SEM of six animals in each group. #P<0.05 was considered
significantly different compared to the normal control group (NORMAL); *P<0.05 was considered significantly
different compared to rats subjected to experimental periodontitis, which received topical application of the
vehicle (HPMC). (ANOVA; Bonferroni’s test).
doi:10.1371/journal.pone.0153716.g001
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Fig 2. Effect of topical application of HPMC/GSNO solutions on the macroscopic (first column) and histological (second column) aspects of
periodontium (A and B) normal maxilla, showing integrity of its components (c. Cementum, pl. Periodontal ligament, ab. Alveolar bone and g. Gingiva). (C
and D)Maxilla subjected to experimental periodontitis that received just the vehicle (HPMC), showing severe bone resorption, inflammatory infiltrate in both
the gingiva and periodontal ligament, extensive cementum destruction and total resorption of the alveolar process, (E and F)Maxilla after 11 days of
experimental periodontitis treated with 2.0 mMHPMC/GSNO showing discrete cell influx and preservation of the alveolar process and cementum. Picrosirius
staining (magnification x40).
doi:10.1371/journal.pone.0153716.g002
Topical S-Nitrosoglutathione Prevents Alveolar Bone Resorption
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Histopathological analysis of the region between the first and second molars of the animal
periodontium that received local applications of HPMC demonstrated accentuated inflammatory
leukocyte infiltration, resorption of the alveolar bone and cementum and collagen fiber derange-
ment within the periodontal ligament, receiving a median score and range of 3(2–3) (Table 2; Fig
2D). The periodontium of rats treated with the HPMC/GSNO 10mM solution showed preserva-
tion of the alveolar process and cementum, reduction of the inflammatory cell infiltration and
partial preservation of the collagen fibers of the periodontal ligament, receiving a median score
and range of 1(0–2) (Table 2; Fig 2F). The histological analysis of the region between the first
and second molars of the control group that was not subjected to EPD (Normal), shows the
structures of the normal periodontium, where fingiva (G), periodontal ligament (PDL), alveolar
bone (AB), cementum (C) and dentin (D) can be observed [(0(0–0)] (Table 2; Fig 2B).
Plasma Bone Alkaline Phosphatase (BALP)
The treatment with GSNO/HPMC (2 and 10 mM) resulted in a significant increase in the
BALP serum levels variation when compared with the control HPMC solution group (Fig 3).
Malonaldehyde (MDA) and Glutathione (GSH) Gingival levels
At the 11th day the group subjected to EPD that received topical applications of the control
HPMC solution showed a significant increase in the MDA level and a reduction in the GSH con-
centration in the gingival tissue, when compared to the normal group. At the same time, treat-
ment with GSNO/HPMC at 10 mM (but not 2.0 mM) significantly reduced the MDA gingival
tissue levels (Fig 4A) and increased GSH levels (Fig 4B) when compared with HPMC group.
Nitrite/Nitrate (NOx) Gingival Levels
The group subjected to EPD that received topical applications of the control HPMC solution
showed a significant increase in NOx levels when compared to the Normal group, on day 11.
Treatment with the HPMC/GSNO solutions (2 and 10 mM) significantly reduced NOx con-
centration when compared with the control HPMC solution group (Fig 5).
Gingival Tissue cytokine levels
It was observed a significant increase in the TNF-α (Fig 6A) and IL-1β (Fig 6B) levels in the
gingival tissue of animals subjected to EPD that received topical applications of control HPMC
solution, when compared with the Normal control group. Topical treatment with the HPMC/
Table 2. Effect of topical application of GSNO/HPMC formulation on histopathologic score of rat
maxillae.
Groups Scores (average values and range)
CONTROL 0 (0–0)
HPMC1 3 (3–3)#
GSNO (0.5 mM)1 2,5 (2–3)
GSNO (2 mM)1 2,5 (2–3)
GSNO (10 mM)1 1,5 (1–2)*
EPD: Experimental periodontal disease.
1 Animals submitted to EDP;
# p< 0.05 versus the normal controls (CONTROL);
* p< 0.05 versus HPMC (animals submitted to EDP and treated with vehicle).
doi:10.1371/journal.pone.0153716.t002
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GSNO 10 mM solution significantly reduced cytokines levels when compared with the control
HPMC solution group (Fig 6A and 6B).
Immunohistochemical staining for iNOS, RANK and TRAP and
nitrotyrosine
Fig 7 illustrates immunostaining for iNOS (Fig 7A), RANK (Fig 7B) and TRAP (Fig 7C) and
nitrotyrosine (Fig 7D) immune expression in the periodontal tissue of animals subjected to EPD
that received topical applications of control HPMC solution, when compared with the Normal
control group. Topical treatment with the HPMC/GSNO 10 mM solution significantly reduced
the immunostaining of iNOS, RANK, TRAP and nitrotyrosine, simultaneously, when compared
with the control HPMC solution group. Accordingly, Fig 8 illustrates immunostaining for iNOS,
RANK, TRAP and nitrotyrosine in the periodontal tissue of animals subjected to EPD that
received local applications of the control HPMC solution (Fig 8C, 8H, 8M and 8R respectively)
on the 11th day compared with the weak staining observed in the Normal control group (Fig 8B,
8G, 8L and 8Q respectively). Local treatment with the HPMC/GSNO 10 mM solution for 11 days
resulted in a considerable reduction in iNOS, RANK and TRAP immunostaining (Fig 8D, 8I, 8N
e 8S respectively) when compared with the control HPMC solution group (Fig 8C, 8H, 8M and
8R, respectively). When the antibodies were replaced with PBS/BSA 5%, no immunostaining was
detected (negative controls; Fig 8A, 8F and 8K and 8P). Fig 8E, 8J, 8O and 8T illustrate the strong
immunostaining observed in the osteoclasts in the control HPMC solution group.
Fig 3. Effect of topical application of HPMC/GSNO solutions on the plasma bone alkaline
phosphatase (BAP) in experimental periodontitis in rats.Data represent the mean ± SEM of six animals
for each group. #P<0.05 was considered significantly different compared to the normal control (NORMAL)
and to the group of animals subjected to experimental periodontitis that received topical applications of the
vehicle (HPMC). Analysis of variance (ANOVA); Bonferroni test.
doi:10.1371/journal.pone.0153716.g003
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Quantitative PCR analysis of RANK, TNF-α and RANKL/OPGmRNA
levels
The group subjected to EPD that received local applications of the control HPMC solution
showed a significant increase in the TNF-α (Fig 9A), RANK (Fig 9B) and in the ratio RANKL/
OPG (Fig 9C) mRNA expression when compared with the Normal control group. Topical
Fig 4. Effect of the topical application of HPMC/GSNO solutions on the oxidative stress markers
malonaldehyde (MDA; A) and reduced glutathione (GSH; B) in experimental periodontitis in rats.Data
represent the mean ± SEM of six animals for each group. #P<0.05 was considered significantly different
compared to the normal control (NORMAL); *P<0.05 was considered significantly different compared to the
group of animals subjected to experimental periodontitis that received topical applications of the vehicle
(HPMC solution). Analysis of variance (ANOVA); Bonferroni test.
doi:10.1371/journal.pone.0153716.g004
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treatment with the HPMC/GSNO 10 mM solution prevented the increase in all cases (Fig 9A,
9B and 9C).
Discussion
In the present study, we demonstrated that topical application of HPMC solution containing
GSNO 10 mM reduces the alveolar bone loss associated with EPD when compared with the
control group that received only the HPMC solution. This result is in accordance with previous
studies demonstrating that both GSNO and S-nitroso-N-acetylpenicilamine (SNAP) reduce
inflammation and bone loss in EPD [11,14]. The absence of anti-reabsorptive or anti-inflam-
matory effects of topical applications of the HPMC/GSNO 2 mM solution suggests that this
GSNO concentration is insufficient to provide a beneficial effect in the present EPD model.
This result is consistent with the literature, which shows that the biological effect of exogenous
NO administration is highly dependent on its local concentration [11,14,31]. HPMC/GSNO
solutions were already shown to release free NO from the spontaneous thermal decomposition
of GSNO according to the equation:
2 GSNO ! GS SGþ 2 NO ð1Þ
where GS-SG is oxidized glutathione, formed after the homolytic S-N bond cleavage, followed
by the formation of a covalent S-S bond [14,19,32]. Free NO locally released at the HPMC/
GSNO solution/gingiva interface is expected to diffuse through the gingiva and periodontal tis-
sues and to be the chemical species responsible for the biological actions herein reported.
In the present HPMC/GSNO solutions the HPMC concentration is 1.25 wt%. At this con-
centration, the HPMC chains are considered to be fully hydrated, with little polymer-polymer
Fig 5. Effect of HPMC/GSNO on the nitrite/nitrate (NOX) levels in experimental periodontitis in rats.
Data represent the mean ± SEM of six animals for each group. # P<0.05 was considered significantly
different compared to the normal control (NORMAL); *P<0.05 was considered significantly different
compared to the group of animals subjected to experimental periodontitis that received topical applications of
the vehicle (HPMC). Analysis of variance (ANOVA); Bonferroni test.
doi:10.1371/journal.pone.0153716.g005
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interactions, comprising thus a viscous polymeric solution and not a hydrogel. HPMC solu-
tions can undergo gelation with HPMC concentrations above 10 wt% and HPMC hydrogels
are frequently used as vehicles for drug delivery [33,34]. The lower HPMC concentration used
in the present study was chosen to facilitate the spreading of the formulation on the affected
gingiva, avoiding thus any inflammation that could be caused by the topical of a hard hydrogel.
Fig 6. Effect of HPMC/GSNO on tumor necrosis factor alpha (TNF-α; A) and interleukin-1β (IL-1β; B) in
experimental periodontitis in rats.Data represent the mean ± SEM of six animals for each group. # P<0.05
was considered significantly different compared to the normal control (NORMAL); *P<0.05 was considered
significantly different compared to the group of animals subjected to experimental periodontitis that received
topical applications of the vehicle (HPMC). Analysis of variance (ANOVA); Bonferroni test.
doi:10.1371/journal.pone.0153716.g006
Topical S-Nitrosoglutathione Prevents Alveolar Bone Resorption
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The observed therapeutic effect of the HPMC/GSNO 10 mM solution on the bone resorp-
tion was associated with an increase in the level of plasma bone alkaline phosphatase (BALP), a
marker of osteoblastic activity, in the serum of animals and a considerable reduction in TRAP
immunostaining (a histochemical marker of osteoclasts observed in multinuclear cells, mainly
osteoclast). These changes were observed in the periodontal tissue of the animals treated with
he HPMC/GSNO 10 mM solution for 11 days, when compared with the control HPMC solu-
tion group, suggesting that the HPMC/GSNO 10 mM solution prevents bone resorption and
also induces bone formation. Accordingly, it has been described that NO donors have benefi-
cial effects on the control of bone resorption (decreased osteoclast activity), and have a milder
anabolic action on bone formation, enhancing osteoblast activity [12,13].
The present study suggests that the protective effect of GSNO on the alveolar bone resorp-
tion is at least in part due to its anti-inflammatory, anti-oxidant and immunomodulatory prop-
erties. We demonstrated that the HPMC/GSNO 10 mM solution significantly reduced the
Fig 7. Quantification of iNOS, RANK, TRAP and nitrotyrosine immunostainning in periodontal tissue of rats submitted to experimental
periodontitis. Data represent the mean ± SEM of four animals for each group. # P<0.05 was considered significantly different compared to the normal
control (NORMAL); *P<0.05 was considered significantly different compared to the group of animals subjected to experimental periodontitis that received
topical applications of the vehicle (HPMC). Analysis of variance (ANOVA); Bonferroni test.
doi:10.1371/journal.pone.0153716.g007
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Fig 8. Representative examples of iNOS (1st row), RANK (2nd row) and TRAP (3rd row)
immunostainning in experimental periodontitis in rats. Staining was performed using periodontal tissues
from normal control animals (b, g, l, q), animals subjected to experimental periodontitis that received topical
applications of HPMC (c, h, m, r) or 10 mM HPMC/GSNO (d, i, n, s). Negative controls were samples of
periodontal tissue where the primary antibody was replaced with PBS-BSA (5%); no immunostaining was
detected (a, f, k, p). Magnification x200. Arrows points to immunostaining osteoclasts in the periodontal tissue
of the control HPMC solution group (Magnification x1000).
doi:10.1371/journal.pone.0153716.g008
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Fig 9. Effect of HPMC/GSNO on tumor necrosis factor alpha (TNF-α; A), RANK (B) and on the ratio
RANKL/OPG (C) mRNA levels in experimental periodontitis in rats.Data represent the mean ± SEM of
six animals for each group. # P<0.05 was considered significantly different compared to the normal control
(NORMAL); *P<0.05 was considered significantly different compared to the group of animals subjected to
experimental periodontitis that received topical applications of the vehicle (HPMC). Analysis of variance
(ANOVA); Bonferroni test.
doi:10.1371/journal.pone.0153716.g009
Topical S-Nitrosoglutathione Prevents Alveolar Bone Resorption
PLOS ONE | DOI:10.1371/journal.pone.0153716 April 26, 2016 15 / 19
TNF-αmRNA in gingival tissue of animals treated with this formulation as well as the gingival
levels of TNF-α and IL-1β, when compared with the control HPMC solution group.
Cytokine participation in periodontal disease is well documented and these substances, par-
ticularly TNF-α and IL-1β, may amplify the inflammatory response causing tissue destruction
and bone loss [31]. It has been reported that IL-1 and TNF-α activate the transcription of
inducible nitric oxide synthase (iNOS) gene resulting in NO production [26]. The HPMC/
GSNO 10 mM solution markedly reduced both iNOS and nitrotyrosine expressions in the peri-
odontal tissues and also reduced the NOx levels in the gingival tissues in comparison with the
control HPMC solution. These findings are in accordance with those reported by Menezes
et al. (2012) who showed that GSNO significantly reduces the gingival levels of IL-1, TNF-α
and NOx, associated with the reduction of iNOS expression in a study conducted using the
same experimental model of the present work [14]. The reduction of iNOS expression associ-
ated with the administration of exogenous GSNO was also described in other studies, notably
in the protective action against secondary injury in an animal model of traumatic brain injury
[35]. This effect has been attributed to the S-nitrosation of the p65 subunit of nuclear factor
kappa B (NFκB) by GSNO, via transnitrosation reaction in the endothelial cells, with conse-
quent inhibition of NFκB activation and down regulation of iNOS. Alternatively, or concomi-
tantly, the mechanism may involve the negative feedback modulation of iNOS by NO itself,
including self-generated and exogenous NO [36]. In this case, the mechanism is considered to
involve the coordination of NO to the iron center of the heme group of iNOS, and can be
extended to other NOS isoforms [37]. The buildup of Heme-NO complex is expected to
strongly inhibit the catalytic activity of the NOSs. In the present case, the source of NO for this
negative feedback action on iNOS, could be attributed to the exogenous NO locally released by
the HPMC/GSNO formulation, according to Eq 1.
The release of large amounts of NO by iNOS has been shown to play a major role in
immune reactions and inflammatory processes, including rheumatoid arthritis and periodontal
disease [23]. NO reacts with oxygen-derived free radicals such as superoxide anion to form
highly reactive molecules such as peroxynitrite anion and the hydroxyl radical and production
of such species may contribute to tissue damage by inducing lipid peroxidation [38]. In accor-
dance, we demonstrated that EPD leads to an oxidative stress in periodontal tissue with conse-
quent generation of reactive oxygen species, indicated by the significant increase in MDA
levels associated with an increase in the nitrotyrosine expression in the periodontal tissue and a
decrease in GSH levels in the gingival tissue. Topical application of HMPC/GSNO 10 mM solu-
tion attenuated the gingival oxidative stress, reestablishing the levels of GSH and decreasing
nitrotyrosine expression and MDA concentration. Together, these results suggest that the pro-
tective effect of the HPMC/GSNO solution is at least partially related to its inhibitory effect on
oxidative stress. Moreover, other studies have indicated that GSNO decreases the formation of
nitrotyrosine and lipid peroxidation in blood, increasing the reduced GSH/oxidized GSH
(GSH/GS-SG) ratio in the brain [39–41].
Considering that alveolar bone loss is a severe consequence of periodontal disease, we inves-
tigated the role of GSNO on bone regulatory RANK/RANKL/OPG pathway in association
with inflammatory and oxidative factors was investigated. It has been demonstrated that TNF-
α can lead to bone destruction by acting direct on osteoclast differentiation [42]. TNF-α acts
together with IL-1 and RANKL, the receptor activator of nuclear factor-κB ligand, which are
abundant in inflammation sites associated with bone destruction, via osteoclast development
and activation [43]. Osteoprotegerin (OPG), expressed by many types of cells as osteoblasts,
counterregulates the excessive bone loss by antagonizing the RANKL-binding to its receptor
RANK [44]. Osteoprotegerin (OPG) and receptor activator of nuclear factor-κB ligand
(RANKL) ratio is a key factor to control osteoclast activity and bone resorption [45]. Our
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results revealed an enhanced expression of RANK in the periodontal tissues of rats submitted
to EPD, mainly in osteoclasts, associated with a decrease in the OPG expression and a signifi-
cant increase in the RANK mRNA levels, as well as in the ratio RANKL/OPG mRNA levels, in
the gingival tissue of animals submitted to EPD (HPMC solution group). The topical applica-
tion of HPMC/GSNO 10 mM solution was able to reduce the RANK expression and increase
the OPG expression in the periodontal tissue of the animals. In addition, the topical application
of the HPMC/GSNO 10 mM solution led to a significant decrease in the RANK and RANKL/
OPG mRNA levels in the gingival tissue, compared with the control HPMC solution group. In
summary, our results provide evidence that the topical application of HPMC/GSNO 10 mM
solution is capable of reducing alveolar bone loss, pro-inflammatory cytokines production and
oxidative stress in an experimental model of periodontal disease, representing a new potential
treatment for periodontal diseases.
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